
Biopharma Builds 100+ AI Drug Team
China Biopharma exec forecasts 2026 medical IPO divergence, with funds favoring BD successes and clear commercialization. Company assembled 100+ AI pharma team amid resurgent investments. BD deals diversify beyond oncology to metabolism, respiratory areas.






